

PROGENICS PHARMACEUTICALS INC  
Form 8-K  
September 15, 2005

---

---

**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**  
**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) September 14, 2005

**Progenics Pharmaceuticals, Inc.**  
(Exact name of registrant as specified in its charter)

<b>Delaware</b>	<b>000-23143</b>	<b>13-3379479</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

<b>777 Old Saw Mill River Road, Tarrytown, New York</b>	<b>10591</b>
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code (914) 789-2800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Item 8.01 Other Events.**

On September 14, 2005, Progenics Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with UBS Securities LLC and CIBC World Markets Corp. with regard to the issuance and sale of 2,500,000 shares of the Company’s common stock, \$.0013 par value per share (the “Offering”). The Company has granted the underwriters an option to buy up to 375,000 additional shares of the Company’s common stock. The underwriters may exercise this option solely for the purpose of covering over-allotments, if any, made in connection with the Offering. The underwriters have 30 days from September 14, 2005 to exercise this option. The price to the public is \$23.90 per share, and proceeds to the Company from the offering, net of expenses, are expected to be approximately \$57.4 million (\$66.0 million, if the underwriters’ over-allotment option is exercised in full). The shares were issued pursuant to a Registration Statement on Form S-3 (File No. 333-126219) previously filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended. A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1 and is incorporated herein by reference.

The Company’s press release announcing the pricing of the underwritten public offering is filed as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

**(c) Exhibits**

**Exhibit**

<b>No.</b>	<b>Description</b>
1.1	Underwriting Agreement dated September 14, 2005, by and between the Company and UBS Securities LLC;
5.1	Opinion of Dewey Ballantine LLP;
23.1	Consent of Dewey Ballantine LLP (contained in Exhibit 5.1 above); and
99.1	Press Release dated September 14, 2005.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROGENICS PHARMACEUTICALS, INC.**

By: /s/ Robert A. McKinney

Robert A. McKinney  
Chief Financial Officer, Vice  
President, Finance and  
Operations and Treasurer

Date: September 15, 2005